Advancing the EVOVLE Platform with Integrated CD2 Costimulation to Enhance the Depth of T-Cell Engager Responses and Prevent Early Therapeutic Exhaustion
- T‑cell engagers have shown positive clinical outcomes across multiple indications, including solid tumors, but currently approved molecules do not provide a direct co‑stimulatory signal
- The EVOLVE platform integrates CD2 co‑stimulation into CD3 multispecifics to enhance T‑cell activation, durability, and functional fitness
- An overview of the EVOLVE multispecific platform and highlight key design features that enable improved T‑cell engagement